China NMPA Inspection - Shanxi Aoyi Aloe Biotechnology Co., Ltd. - July 05, 2019

The National Medical Products Administration (NMPA) issued an official notification on July 5, 2019, concerning an unannounced inspection conducted on Shanxi Aoyi Aloe Biotechnology Co., Ltd. This public announcement, identified by index number JGXX-2020-1977, signifies a regulatory action undertaken by China's primary authority overseeing drugs, medical devices, and cosmetics. Unannounced inspections are a standard procedure within the NMPA's regulatory framework, designed to ensure continuous compliance with manufacturing standards, quality control, and safety protocols without advance notice to the inspected entity. The notification confirms that Shanxi Aoyi Aloe Biotechnology Co., Ltd. was subjected to such an inspection. However, the document itself is a notification of the inspection's occurrence rather than a detailed report. Consequently, it does not specify the precise dates when the inspection took place, nor does it provide any information regarding main violations or issues discovered during the audit. Furthermore, the notification does not outline any specific required actions, corrective measures, or enforcement steps that may have resulted from the NMPA's findings. Its primary purpose is to publicly acknowledge the regulatory engagement with the company.